Weight Loss Shot Results: The Real Timeline

The average timeline, month by month

All figures are trial-population averages for semaglutide 2.4 mg with lifestyle support; individual trajectories vary substantially in both speed and total.

Why the first months look slow: titration by design

The early curve is flat on purpose. Semaglutide starts at 0.25 mg weekly, a dose chosen for tolerability rather than effect, and steps up roughly monthly through 0.5, 1, and 1.7 toward the 2.4 mg maintenance dose. Tirzepatide follows the same logic from 2.5 mg toward as much as 15 mg. The full appetite effect arrives with the full dose, months in.

This is the single most misunderstood fact in the category, and it has a direct cost consequence: people who quit in month two have paid for the ramp and left before the payoff the trials describe. It also frames pricing structures: flat-rate channels like NovoCare's $499 tier cost the same during titration, while dose-priced compounded programs, compared in the price overview, are cheapest precisely during the slow early months.

The corollary is a fair evaluation window. Judging either molecule before reaching a maintenance dose measures the ramp, not the drug, which is why prescribers typically schedule the first formal progress review months in, once full dosing has had time to show its effect. Setting that expectation on day one, alongside the budget, is the cheapest anti-quitting tool available in the whole category.

The tirzepatide curve, and the head-to-head

Tirzepatide's trajectory is similar in shape and higher in destination: SURMOUNT-1 averaged 20.9% at 72 weeks, and the SURMOUNT-5 head-to-head measured 20.2% versus 13.7% for semaglutide under matched conditions, a gap that accumulates across the timeline rather than appearing at the end.

For anyone choosing between molecules on the basis of the curves, the full comparison weighs the six-point average difference against the price difference by channel. One frontier note for completeness: retatrutide averaged 24.2% in a phase 2 trial but remains unapproved and available only within clinical trials, so it belongs in the watch column, not the plan.

The same discipline applies to switching: changing molecules because month two disappointed repeats the ramp and the ramp months, while switching after a genuine maintenance-dose plateau is the version the head-to-head data actually supports considering, with a prescriber managing the transition.

The plateau: expected, not a failure

Around months 12–15 on semaglutide, average weight stabilizes. The plateau is physiology, the new equilibrium between the medication's appetite effects and the body's adaptation, and it appears in every major trial; more months at the same dose do not indefinitely produce more loss.

What the plateau means practically: it is the point where the goal shifts from losing to maintaining, and where treatment decisions get made with a provider, continuing for maintenance, adjusting dose, or switching molecules if the total reached is well short of expectations. Trial data on discontinuation is sobering in the other direction: stopping tends to bring gradual regain, which is why the honest budgeting frame treats these as ongoing costs, not a twelve-month project with a finish line.

Four factors reliably shift individual curves around the averages. Dose and adherence: missed weeks flatten the slope more than any other controllable variable. Starting point: higher baseline weights tend to produce larger absolute losses at similar percentages. Lifestyle support: every major trial paired medication with diet and activity counseling, so the published averages already assume that context rather than the medication alone. And molecule: the tirzepatide curve simply runs higher on average at every timepoint. None of these rewrite the shape, titration, steepening, plateau; they move its height.

What the timeline does to the cost math

Combining the curve with 2026 prices produces the numbers that should drive planning:

• Reaching the ~10% average marker takes roughly 6 months: about $600–$1,800 compounded, or about $3,000 via $499 flat-rate brand channels.
• Reaching the ~15% trial average takes 12–15-plus months: roughly $1,200–$4,500 compounded, $6,000–$7,500 brand self-pay, $300–$750 with an insurance copay.
• Quitting at month 2 spends $200–$1,000 to exit before the steep part of the curve, the worst cost-per-result on the whole table.

Insurance changes none of the shape and all of the totals: at a $25–$50 copay, even the full arc to plateau costs less than three months at typical cash prices, which is why checking coverage before choosing a cash channel is step one of any timeline budget rather than an afterthought.

The conclusion is not "spend more"; it is that channel choice and staying power dominate the economics, so pick a monthly price sustainable for a year-plus, per the cheapest options ranking, and confirm eligibility and fit with a licensed provider first. To match a sustainable plan to your budget, compare program pricing here.